Sugi Predict

Sugi Predict / Compounds / Fluorescein

Fluorescein

Fluorescein

SCHEMBL1034246

O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21.OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 9/20 0.69
▸ MAPT P10636 4/20 0.69
▸ MEN1 O00255 3/20 0.69
▸ KMT2A Q03164 3/20 0.69
▸ HTT P42858 2/20 0.69
▸ TDP1 Q9NUW8 2/20 0.69
▸ HPGD P15428 2/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ RECQL P46063 1/20 0.69
▸ BLM P54132 1/20 0.69
▸ SMAD3 P84022 1/20 0.69
▸ PRMT1 Q99873 1/20 0.69
▸ ACE2 Q9BYF1 1/20 0.69
▸ LMNA P02545 3/20 0.50
▸ GPR55 Q9Y2T6 2/20 0.50
▸ ALOX12 P18054 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ CYP3A4 P08684 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorescein SCHEMBL3485550 1.00 FTO (0.69) FTOMAPTMEN1KMT2AHTT
SCHEMBL29661300 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
SCHEMBL20777527 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
SCHEMBL10710403 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
SCHEMBL3695146 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
SCHEMBL1029869 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
SCHEMBL597089 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
SCHEMBL869219 0.87 MAPT (0.59) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL1973302 0.84 FTO (0.97) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL29025259 0.83 FTO (0.89) FTOMAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117165655-A Rapid pathogen-specific enzymatic drug sensitivity analysis method 浙江大学 2023-12-05 — — CN claimed
US-20130130292-A1 Method for detecting replication or colonization of a biological therapeutic GENELUX CORPORATION 2013-05-23 — — US claimed
CN-101541944-B Sterilization indicator AMERICAN STERILIZER CO 2013-05-22 — — CN claimed
CN-101541944-A Sterilization indicator AMERICAN STERILIZER CO (US) 2009-09-23 — — CN claimed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 — — US disclosed
US-11963968-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-04-23 — — US disclosed
EP-3204032-B1 CHIMERIC MOLECULE COMPRISING CRISPR/CAS OR CAS9 NUCLEASE AND AT LEAST ONE GUIDE RNA TARGETING PMCA2 GENE LOCUS AND FUSED, COMPLEXED OR LINKED TO AN ANIONIC FLUORESCENT PROTEIN, AND ITS USE IN THE TREATMENT OF DEAFNESS OR DISORDERS THEREOF MASSACHUSETTS EYE & EAR INFIRMARY (US) 2024-03-27 — — EP disclosed
EP-3212221-B1 EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES IN VITRO AND IN VIVO MASSACHUSETTS EYE & EAR INFIRMARY (US) 2023-12-06 — — EP disclosed
WO-2023183625-A2 BIOSENSOR AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2023-09-28 — — WO disclosed
US-20230277574-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2023-09-07 — — US disclosed
US-11590152-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2023-02-28 — — US disclosed
US-20220281941-A1 EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-09-08 — — US disclosed
WO-1996031618-A1 ISOLATED FrpB NUCLEIC ACID MOLECULE AND VACCINE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1996-10-10 — — WO disclosed
US-5547670-A POLYPEPTIDES IMCLONE SYSTEMS INCORPORATED (US) 1996-08-20 — — US disclosed
EP-0717774-A1 PRODUCTION OF GONORRHEAL PI PROTEINS AND VACCINES IN E. COLI AND SALMONELLA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1996-06-26 — — EP disclosed
EP-0702729-A1 CHEMICAL PROCESS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES IMCLONE SYSTEMS, INC. (US) 1996-03-27 — — EP disclosed
US-5437977-A DNA probe signal amplification Segev, David (IL) 1995-08-01 — — US disclosed
WO-1995004133-A1 PRODUCTION OF GONORRHEAL PI PROTEINS AND VACCINES IN E. COLI AND SALMONELLA THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1995-02-09 — — WO disclosed
WO-1994029485-A1 CHEMICAL PROCESS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES IMCLONE SYSTEMS INCORPORATED (US) 1994-12-22 — — WO disclosed
EP-0450594-A2 DNA probe signal amplification Segev, David (US) 1991-10-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281941-A1 EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR HES1, NOTCH1, NOTCH2 FTO 4771/4885MAPT 3320/4885MEN1 254/4885
US-11590152-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 FTO 4042/4885MAPT 3170/4885MEN1 66/4885
US-20230277574-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 FTO 4042/4885MAPT 3170/4885MEN1 66/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 FTO 4771/4885MAPT 3320/4885MEN1 254/4885
US-11963968-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 FTO 4042/4885MAPT 3170/4885MEN1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.